1. Oral hypoglycaemic effect of GLP-1 and DPP4 inhibitor based nanocomposites in a diabetic animal model
- Author
-
Jouni Hirvonen, Mikko Airavaara, Neha Shrestha, Francisca Araújo, Mohammad-Ali Shahbazi, Ermei Mäkilä, Janne-Juhani Raula, Esko I. Kauppinen, Bruno Sarmento, Jarno Salonen, Hélder A. Santos, and Maria João Gomes
- Subjects
Glucagon-like peptide-1 ,Blood Glucose ,Silicon ,medicine.medical_specialty ,medicine.medical_treatment ,ta221 ,Administration, Oral ,Pharmaceutical Science ,02 engineering and technology ,Methylcellulose ,010402 general chemistry ,01 natural sciences ,Diabetes Mellitus, Experimental ,Nanocomposites ,chemistry.chemical_compound ,Glucagon-Like Peptide 1 ,Oral administration ,In vivo ,Internal medicine ,Intestine, Small ,medicine ,Dipeptidyl peptidase-4 ,Animals ,Rats, Wistar ,ta317 ,Chitosan ,Dipeptidyl-Peptidase IV Inhibitors ,ta114 ,Nicotinamide ,Insulin ,Type 2 Diabetes Mellitus ,021001 nanoscience & nanotechnology ,Streptozotocin ,Ex vivo ,0104 chemical sciences ,3. Good health ,Oral delivery ,Endocrinology ,Diabetes Mellitus, Type 2 ,chemistry ,Porous silicon nanoparticles ,Nanoparticles ,Drug Therapy, Combination ,0210 nano-technology ,medicine.drug - Abstract
Glucagon-like peptide-1 (GLP-1), an incretin hormone, is used for type 2 diabetes mellitus (T2DM) treatment because of its ability to stimulate insulin secretion and release in a glucose-dependent manner. Despite of its potent insulinotropic effect, oral GLP-1 delivery is greatly limited by its instability in the gastrointestinal tract, poor absorption efficiency and rapid degradation by dipeptidylpeptidase-4 (DPP4) enzyme leading to a short half-life (~2min). Thus, a multistage dual-drug delivery nanosystem was developed to deliver GLP-1 and DPP4 inhibitor simultaneously. The system comprised of chitosan-modified porous silicon (CSUn) nanoparticles, which were coated by an enteric polymer, hydroxypropylmethylcellulose acetate succinate MF, using aerosol flow reactor technology. A non-obese T2DM rat model induced by co-administration of nicotinamide and streptozotocin was used to evaluate the in vivo efficacy of the nanosystem. The oral administration of H-CSUn nanoparticles resulted in 32% reduction in blood glucose levels and ~6.0-fold enhancement in pancreatic insulin content, as compared to the GLP-1+DPP4 inhibitor solution. Overall, these results present a promising system for oral co-delivery of GLP-1 and DPP4 inhibitor that could be further evaluated in a chronic diabetic study.
- Published
- 2016
- Full Text
- View/download PDF